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Abstract
Background: The study objective is to assess the effectiveness and economic impact of a structured programme to
support patient involvement in centre-based haemodialysis and to understand what works for whom in what
circumstances and why. It implements a program of Shared Haemodialysis Care (SHC) that aims to improve
experience and outcomes for those who are treated with centre-based haemodialysis, and give more patients
the confidence to dialyse independently both at centres and at home.
Methods/Design: The 24 month mixed methods cohort evaluation of 600 prevalent centre based HD patients is
nested within a 30 month quality improvement program that aims to scale up SHC at 12 dialysis centres across England.
SHC describes an intervention where patients who receive centre-based haemodialysis are given the opportunity to
learn, engage with and undertake tasks associated with their treatment.
Following a 6-month set up period, a phased implementation programme is initiated across 12 dialysis units
using a randomised stepped wedge design with 6 centres participating in each of 2 steps, each lasting 6 months. The
intervention utilises quality improvement methodologies involving rapid tests of change to determine the most
appropriate mechanisms for implementation in the context of a learning collaborative. Running parallel with
the stepped wedge intervention is a mixed methods cohort evaluation that employs patient questionnaires
and interviews, and will link with routinely collected data at the end of the study period. The primary outcome measure
is the number of patients performing at least 5 dialysis-related tasks collected using 3 monthly questionnaires. Secondary
outcomes measures include: the number of people choosing to perform home haemodialysis or dialyse independently
in-centre by the end of the study period; end-user recommendation; home dialysis establishment delay; staff impact and
confidence; hospitalisation; infection and health economics.
Discussion: The results from this study will provide evidence of impact of SHC, barriers to patient and centre level
adoption and inform development of future interventions to support its implementation.
Trial registration: ISRCTN Number: 93999549, (retrospectively registered 1st May 2017); NIHR Research Portfolio: 31566
Keywords: Randomised stepped-wedge, Breakthrough series collaborative, Patient activation, Supported self-care,
Shared Haemodialysis Care
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Background
In the UK approximately 23,000 people attend in-centre
facilities three times a week to receive haemodialysis
(HD) [1]. Structural arrangements in dialysis units tend
to create an environment in which patients become pas-
sive recipients of their care, engaging little with their
own treatment. There is considerable evidence of the
benefits of supported self-care in long term conditions
[2, 3]. Low health literacy amongst dialysis patients is as-
sociated with worse survival [4] whereas self-motivation
and patient education results in preferable clinical param-
eters e.g. phosphate control [5] and fluid balance [6]. Dia-
lysis services are experiencing considerable pressure to
deliver high quality care in the face of fiscal challenge,
often when approaching capacity. An important mechan-
ism to ensure that quality of care is maintained is to
engage service users as true partners in their own care;
self-management is an ambition in “Kidney Health: Deliv-
ering Excellence” [7]. The tradition of self-care extends to
the 1,113 UK patients who performed haemodialysis at
home in 2014 [1]. In addition to the better survival [8]
and quality of life [9] associated with home HD (HHD),
increasing HHD from 4.1% in the UK to the 12.9% used in
Australia and New Zealand [10] would lead to estimated
annual savings to the UK National Health Service of
£16M (an increase of 1400 people treated with HHD at a
saving of £12000 per patient per year [11]).
SHC describes an intervention where people treated
with in-centre HD are given the opportunity to learn
tasks relating to their own dialysis treatment. HD treat-
ment is standardised requiring a number of key steps for
its preparation, delivery and discontinuation. For SHC to
be adopted consistently across dialysis services several
changes become necessary. Health care professionals re-
quire a change in their roles from one in which they
undertake repetitive tasks for patients to one where they
become educators and facilitators in order to support
patients to take a greater role in their own care. Patients
require encouragement to change their expectation of
care to one where they become involved in their own
treatment. This approach gives centre based dialysis pa-
tients access to the benefits of participating in their own
care while increasing opportunities for home dialysis.
Methods/Design
Aim
This study aims to assess the effectiveness and economic
impact of a structured programme to encourage patient
involvement in centre-based haemodialysis (HD), and to
understand what works for whom in what circumstances
and why. This supported self-care intervention is intended
to improve experience and outcomes for those who are
treated with centre-based haemodialysis, and give more
patients the confidence to dialyse independently both at
centres and at home.
Study design and timeline
End points will be quantified following a stepped-wedge
introduction of the intervention, in which 6 centres are
randomly allocated to start implementation in step 1,
with the remaining 6 starting in step 2. Each step lasts 6
months, and including the baseline phase the study lasts
24 months. The study phases are outlined in Fig. 1 and
the schedule of instruments in Table 1. The programme
entered the baseline phase in October 2016.
Study setting and participants
The objective is to recruit 600 prevalent in-centre HD pa-
tients from the 12 participating renal centres during the
baseline phase. All suitable prevalent dialysis patients at
selected centres are entered into a screening log and from
this patients are approached and given the opportunity to
participate in the research with the intention of recruiting
up to 50 patients at each site. Once eligible patients have
been given study information, informed consent is taken
by trained delegated members of the local research team
at a subsequent dialysis session. This includes consent for
data linkage to hospital episode and UK Renal Registry
data. Participants are also given the opportunity to be in-
volved in interviews and workshops conducted by the
evaluation team. As the study is questionnaire based we
anticipate that more than 90% of approached patients will
agree to be recruited to the study.
Inclusion/exclusion criteria
Inclusion criteria are for patients to be established on
centre based HD and have capacity to give written in-
formed consent. Exclusion criteria are those who are too
unwell to engage in the study as judged by the clinical
team or unable to understand written and verbal com-
munication in English.
Intervention
The intervention at the centre of this study is that centre
based HD patients are given the choice to undertake treat-
ment related tasks, listed in Table 2. These range from
performing observations, preparatory hygiene, setting up
the dialysis machine, securing dialysis access, program-
ming the machine, initiating monitoring and discontinu-
ing/completing dialysis.
A series of learning events are planned with teams com-
prising approximately five individuals from each partici-
pating site. These include clinicians, nursing staff, patient
partners and additional relevant personnel (e.g. psycholo-
gist, service managers as determined by individual sites).
The learning events are designed to review the objectives
of SHC, share patient and clinician experience, teach and
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review quality improvement methodologies, and develop
rapid tests of change to optimise local implementation.
Learning is underpinned through the SHC website [12],
teleconferences, social media platforms and newsletters,
while staff education is supported by a bespoke nursing
training course developed during pilot work [13]. A pa-
tient advisory group has been established in order to sup-
port their involvement and ensure that the programme
maintains patient focussed objectives.
Outcome measures and quantitative data collection
Efficacy Endpoints - The primary binary outcome is a
change in the proportion of sampled HD patients com-
pleting 5 or more out of 14 tasks (Table 2). The secondary
binary outcome is an absolute increase HHD and in centre
independent dialysis of 4% within participating centres.
Quality and Safety Endpoints - Changes in patient ac-
tivation [14]; quality of life (EQ-5D-5L) [15]; POS-S
Renal symptom score [16] will be assessed using the
“Your Health Survey” developed as part of the NHS
England supported Transforming Participation in
Chronic Kidney Disease program [17]. Responses to this
survey will be transferred to the UK Renal Registry and
uploaded to PatientView [18] for participating patients
to review themselves and to be used to inform clinical
consultations. Hospitalisation (all-cause and cause spe-
cific) will inform cost, benefits and harms assessments.
The economic evaluation will take an NHS and social care
perspective and will compare SHC with usual care in a
cost-utility analysis based on a cost-per quality adjusted
life years (QALYs) approach. The EQ-5D-5L will be used
to measure health related quality of life at baseline, six and
12 months. Resource use will be estimated from a range
of sources including an adapted cost questionnaire [19]
and non-participant observation to quantify time spent
performing HD tasks by patients and staff.
Hospital Episode Summary data will be used for infor-
mation on comorbidity at the time of recruitment (by
reviewing diagnosis codes from admissions up to 5 years
prior to the start of the SHAREHD programme), hospi-
talisation (all cause and cause specific) before and after
the implementation of SHAREHD to assess for benefits
and harms, and inform health economic analyses. Simi-
lar datasets and diagnostic codes have been used to
identify harms from hospital and home-based haemodi-
alysis therapies and assess cost [20].
Qualitative investigation and realist evaluation
Realist evaluation will be conducted complementary to
the quantitative primary and secondary endpoints to
Fig. 1 Stepped wedge evaluation of quality improvement to facilitate shared haemodialysis care
Table 1 Data collection instruments
Instrument Frequency Content
Demography form Once, at start Ethnicity, educational level, home and employment
circumstances (adapted from [27])
Tasks questionnaire 3 monthly 15 dialysis related tasks (Table 2)
Think Kidneys questionnaire 6 monthly POS-S Renal symptom score [16], quality of life (EQ-5D-5L [15]),
patient activation measure [14]
SHAREHD uptake indicators form 6 monthly Meta-cognition (memory & concentration [28]), Health literacy
[29], dialysis access and attitudes to self-needling
Health economic form 6 monthly Transport, dependants, arrangements made and duration of
attendance for patient and companions who also attend dialysis
Status change form Event Driven Transplantation, mortality, changes in dialysis modality & location
Fotheringham et al. BMC Nephrology  (2017) 18:335 Page 3 of 7
determine if and how SHC works, for whom and in what
context. Building on existing theories gained from litera-
ture, key stakeholders and the Yorkshire SHC pilot, a logic
model will be constructed. This model will be developed
throughout the project, and used to refine and test specific
relevant hypotheses. Key contextual service characteristics
will be determined across the units to further understand
the linkage between variability in context, implementa-
tion and outcomes, and to inform interview sampling
strategies. Semi-structured interviews will be conducted
before and after the intervention with approximately 24
patients and 24 members of staff across participating
sites. Programme theory and expert opinion will inform
a stakeholder map from which key individuals will be
selected for interview.
Allocation and blinding
The study statistician (SJW) used computer generated
random numbers to produce a random allocation se-
quence for the 12 dialysis centres; with 6 units rando-
mised to intervention in the first step and the remaining
6 units randomised to the intervention in the step two.
There was no patient-level stratification. The study man-
ager (SL) was told of the random allocation sequence
and then informed the 12 dialysis centres when they
would be receiving the SHAREHD intervention. Individ-
ual trial participants at the 12 dialysis centres are re-
cruited and enrolled by local clinical research network
nursing staff. The study participants, centres and re-
search staff are unblinded.
Sample size calculation
Assuming that the baseline level of completing 5 tasks is
around 15%, an ICC of 0.05 and an average cluster size of
25 HD patients; then using the STATA stepped wedge
command [21] with a stepped wedge design of 3 steps (in-
cluding baseline) and 12 clusters, with 6 clusters rando-
mised at each step, we will have 90% power to detect an
increase in the event rate from 15% to 30% as statistically
significant at the 5% two-sided level. If we assume that the
baseline level of the secondary outcome measure of HHD
is around 2% in participating clusters an ICC of 0.05 and
an average cluster size of 25 HD patients; then with a
stepped wedge design of 3 steps (including baseline) and
12 clusters, with 6 clusters randomised at each step will
we have 80% power to detect an increase in the event rate
from 2% to 7.2% as statistically significant at the 5% two-
sided level. In recognition of a mortality rate of 17% per
annum [20], a background renal transplantation rate and
to mitigate the risk of incomplete data collection, the tar-
get recruitment per participating site was increased to 50.
Data collection
Paper questionnaires will be batched, and securely trans-
ferred to the Sponsor site (Sheffield Teaching Hospitals
NHS Foundation Trust)1 to be entered into the research
database and will be retained securely for audit purposes.
Interview audio recordings will encrypted, pseudo-
anonymised and be destroyed after transcription.
Statistical analysis plan
The primary and secondary outcomes will be compared
across the intervention and control clusters using a longi-
tudinal random (or multi-level mixed) effects logistic re-
gression model (with time, phase or step), group
(intervention or control) and individual patient character-
istics such as age and gender as covariates; and the renal
unit or cluster as a random effect. These models will take
into account the clustering of outcomes by units. The
odds ratio estimate for the intervention effect and its asso-
ciated confidence interval will be reported from the
model. Statistical associations between patient characteris-
tics, dialysis schedules and outcomes will also be explored.
Monitoring
The quality improvement initiative and cohort study is
monitored through a project board, evaluation and pa-
tient advisory groups. The evaluation board monitors
the progress of the study including data completeness
and safety issues.
Table 2 Shared Haemodialysis Care treatment tasks (note some tasks are mutually exclusive)
Patient preparation Machine Preparation & Dialysis Initiation During and after dialysis
Measuring your weight Lining your dialysis machine Responding to your machine alarms
Measuring your blood pressure and pulse Priming your dialysis machine Disconnecting the lines and completing your dialysis
Measuring your temperature Preparing your dressing pack Applying pressure to your needle sites OR Locking your
own tunnelled line
Washing your hands prior Programming your dialysis machine Giving your own anaemia injections (such as epoetin)
Needling your fistula/graft OR Preparing
your tunnelled line
Connecting the lines to your fistula/graft/
tunnelled line and commencing dialysis
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Discussion
The objective of this evaluation is to better understand
the impact of participating in treatment related tasks
among people who receive dialysis at treatment centres.
The outcomes that we will examine through this study
include access to home or independent dialysis in centre,
quality of life, symptom scores, as well as harms includ-
ing infection and hospitalisation. The intervention at the
heart of this protocol is to create an environment where
dialysis nurses consistently give patients the opportunity
to choose to learn and undertake treatment related
tasks. It is our plan that this will be implemented at par-
ticipating sites through a series of workshops based on
quality improvement methodologies, nested in a struc-
tured collaborative in which teams from participating
sites are able to share learning in order to identify the
most effective approaches.
Patient involvement in health care comes in a variety
of forms including engaging people to keep healthy,
shared decision making, choosing a provider and self-
management support [22]. The evolution of person-
centred care has progressed over several decades con-
tributed to by a succession of key documents, including
most recently the NHS five year forward view [23]. Pa-
tient training is central to the provision of dialysis home
therapies in order to provide individuals with the re-
quired skills necessary to manage their condition in the
community away from the hospital services. Alterna-
tively those who receive their dialysis treatment at cen-
tres are much less likely to be engaged in their own
treatment. There is robust evidence that informing pa-
tients about their condition and providing educational
opportunities for them to engage in their own care leads
to improved outcomes [2]. Current arrangements limit
opportunities for centre-based dialysis patients to take a
significant role in improving their own outcomes.As a
consequence, the existing approach is potentially disad-
vantageous to centre based HD patients and could be
challenged on the basis of equity, since those who take
up HHD tend to have lower deprivation scores and are
more likely to be Caucasian.
The strengths of our protocol include the stepped
wedge design with a random allocation to reduce the
risk of bias, particularly relevant in a quality improve-
ment intervention. We selected instruments on the basis
of clear evidence of their utility. The Patient Activation
Measure (PAM) [24] is being used under licence from
NHS England to explore factors that impact on readi-
ness to participate in dialysis related tasks. Low patient
activation is associated with a range of poorer healthcare
outcomes including readmission to hospital, medical
errors and loss of confidence in healthcare providers
[25]. The questions on mobility, symptom burden,
cognition, health literacy and attitudes to self-needing
included in our questionnaires (Table 1) were identified
though our pilot work as potentially impacting on the
individual’s ability to participate in HD tasks. Identify-
ing barriers to involvement is clearly important particu-
larly as the SHC concept is that patients are supported
to take on as much or as little as they feel able to do. A
small amount of engagement is meaningfully different
from an environment where participation is discour-
aged. The duration of the study is sufficient to assess
whether perceived benefits to patients are sustained or
whether the repetitive nature of dialysis treatment re-
sults in a loss of enthusiasm for engagement over
time. Patient partners are central in the design of the
intervention, selection of endpoints and instruments
and ensuring outputs remain relevant to the end-user
(co-production).
The challenges of the adopted approach include com-
peting pressures that health care professionals face in
their day to day work and that the heterogeneity of HD
units may limit the effectiveness of the intervention. To
address these concerns we have adopted quality im-
provement methodologies that are intentionally tailored
to support local configuration. Participant drop-out dur-
ing the course of the 24 month protocol has been miti-
gated by doubling the initial cohort size above that
required by the power calculation.
Summary
This prospective 12 site cohort study sets out to relate
the impact of learning treatment related tasks for people
who receive centre-based dialysis. The objective is to
support a cultural change where people treated with dia-
lysis are encouraged to become active partners in their
care irrespective of the location of their treatment. The
instruments and outcome measures have been selected
because of their relevance to evaluating the barriers
and drivers of supported self-care in the centre based
HD environment. The stepped-wedge design is under-
pinned by intervention delivery within a quality im-
provement collaborative. Clearly that approach requires
sensitivity to the abilities and preferences of patients
while creating an environment where participation is
normalised.
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